Evidence map›Paper›PMID 37869789›Full record

ArticleEmerging microbes & infections2023

Previous exposure to Spike-providing parental strains confers neutralizing immunity to XBB lineage and other SARS-CoV-2 recombinants in the context of vaccination.

Rahul K Suryawanshi, Taha Y Taha, Maria McCavitt-Malvido, Ines Silva, Mir M Khalid, Abdullah M Syed, Irene P Chen, Prachi Saldhi, Bharath Sreekumar, Mauricio Montano and 23 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 4 institutions in 2 countries.

Rahul K SuryawanshiGladstone Institutes, San Francisco, CA, USA.
Taha Y TahaGladstone Institutes, San Francisco, CA, USA.
Maria McCavitt-MalvidoGladstone Institutes, San Francisco, CA, USA.
Ines SilvaCurative Inc., Monrovia, CA, USA.
Mir M KhalidGladstone Institutes, San Francisco, CA, USA.
Abdullah M SyedGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Irene P ChenGladstone Institutes, San Francisco, CA, USA.
Prachi SaldhiDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Bharath SreekumarGladstone Institutes, San Francisco, CA, USA.
Mauricio MontanoGladstone Institutes, San Francisco, CA, USA.
Kafaya ForesytheDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Takako TabataGladstone Institutes, San Francisco, CA, USA.
G Renuka KumarGladstone Institutes, San Francisco, CA, USA.
Alicia Sotomayor-GonzalezDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Venice ServellitaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Amelia GliwaDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Jenny NguyenDepartment of Laboratory Medicine, University of California, San Francisco, CA, USA.
Noah KojimaCurative Inc., Monrovia, CA, USA.
Teresa ArellanorCurative Inc., Monrovia, CA, USA.
Aallyah BussanichCurative Inc., Monrovia, CA, USA.
Victoria HessCurative Inc., Monrovia, CA, USA.
Maria ShacreawCurative Inc., Monrovia, CA, USA.
Lauren LopezCurative Inc., Monrovia, CA, USA.
Matthew BrobeckCurative Inc., Monrovia, CA, USA.
Fred TurnerCurative Inc., Monrovia, CA, USA.
Yuzhu WangCurative Inc., Monrovia, CA, USA.
Sydney GhazarianCurative Inc., Monrovia, CA, USA.
Gregg DavisCurative Inc., Monrovia, CA, USA.
Diviana RodriguezCurative Inc., Monrovia, CA, USA.
Jennifer DoudnaGladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA.
Lee SpraggonCurative Inc., Monrovia, CA, USA.
Charles Y ChiuDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Melanie OttGladstone Institutes, San Francisco, CA, USA.
Gladstone Institutes · USUniversity of California, San Francisco · USUniversity of California System · USQuantitative BioSciences · US

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$103.4M
RESEARCH PROJECT 2U19AI135990 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDREJ SALI · 2018 to 2026
$21.4M
Suppression of Host Antiviral Responses by a SARS-CoV-2 Histone MimeticF31AI164671 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHEN, IRENE PO-RU · 2021 to 2022
$82k
NIAID NIH HHS F31 AI164671NIAID NIH HHS U19 AI135990NIAID NIH HHS U19 AI171110
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 recombinants is of particular concern as they can result in a sudden increase in immune evasion due to antigenic shift. Recent recombinants XBB and XBB.1.5 have higher transmissibility than previous recombinants such as "Deltacron." We hypothesized that immunity to a SARS-CoV-2 recombinant depends on prior exposure to its parental strains. To test this hypothesis, we examined whether Delta or Omicron (BA.1 or BA.2) immunity conferred through infection, vaccination, or breakthrough infection could neutralize Deltacron and XBB/XBB.1.5 recombinants. We found that Delta, BA.1, or BA.2 breakthrough infections provided better immune protection against Deltacron and its parental strains than did the vaccine booster. None of the sera were effective at neutralizing the XBB lineage or its parent BA.2.75.2, except for the sera from the BA.2 breakthrough group. These results support our hypothesis. In turn, our findings underscore the importance of multivalent vaccines that correspond to the antigenic profile of circulating variants of concern and of variant-specific diagnostics that may guide public health and individual decisions in response to emerging SARS-CoV-2 recombinants.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralAntigenic Drift and ShiftBreakthrough InfectionsHumansVaccinationAntibodies, NeutralizingAntibodies, Viralhumoral immunityneutralizationrecombinantsSARS-CoV-2vaccine

Identifiers

PMID37869789
PMCPMC10619466
OpenAlexW4387865478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.